Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.16.6923

The CCND1 G870A Gene Polymorphism and Leukemia or Non-Hodgkin Lymphoma Risk: a Meta-analysis  

Qin, Ling-Yan (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Zhao, Li-Gang (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Chen, Xu (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Yang, Zheng (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Mo, Wu-Ning (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.16, 2014 , pp. 6923-6928 More about this Journal
Abstract
In recent years, mounting evidence has indicated that the CCND1 G870A gene polymorphism, which impacts the mitotic cell cycle, may influence leukemia or non-Hodgkin lymphoma risk. Unfortunately, the previous results were inconsistent. Therefore, a meta-analysis was performed to obtain a more precise estimation of any association. We conducted a search in PubMed, Embase and CNKI covering all published papers up to March, 2014. A total of 9 publications including 10 case-control studies met the inclusion criteria. Odds ratios (ORs) and their 95% confidence intervals (95%CIs) were applied to assess association. The pooled ORs showed significant association in non-Hodgkin lymphoma (comparison A vs G: OR= 1.114, 95%CI=1.053-1.179, p=0.000; homozygote comparison AA vs GG: OR=1.245, 95%CI=1.110-1.396, p=0.000; heterozygote comparison AG vs GG: OR=1.095, 95%CI=1.000-1.199, p=0.05; dominant model AA/GA vs GG: OR=1.137, 95%CI=1.043-1.239, p=0.003; and recessive model AA vs GA/GG: OR=1.177, 95%CI=1.066-1.301, p=0.001). However, there was no association between the CCND1 G870A polymorphism and leukemia risk. In conclusion, the CCND1 G870A polymorphism may increase risk of non-Hodgkin lymphoma, but not leukemia. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with leukemia and non-Hodgkin lymphoma risk.
Keywords
Leukemia; non-Hodgkin lymphoma; CCND1 gene; polymorphism; meta-analysis;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Advani AS, Hunger SP, Burnett AK (2009). Acute leukemia in adolescents and young adults. Semin Oncol, 36, 213-26.   DOI
2 Akkiz H, Bayram S, Bekar A, Akgollu E, Ozdil B (2010). Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: case-control study. Cancer Epidemiol, 34, 298-302.   DOI   ScienceOn
3 Bala S, Peltomaki P (2001). CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer. Cancer Res, 61, 6042-5.
4 Bassig BA, Lan Q, Rothman N, Zhang Y, Zheng T (2012). Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol, 2012, 978930.
5 Bedewy AM, Mostafa MH, Saad AA, et al (2013). Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer. J BUON, 18, 227-38.
6 Betticher DC, Thatcher N, Altermatt HJ, et al (1995). Alternate splicing produces a novel cyclin D1 transcript. Oncogene, 11, 1005-11.
7 Catarino R, Coelho A, Nogueira A, et al (2012). Cyclin D1 polymorphism in non-small cell lung cancer in a Portuguese population. Cancer Biomark, 12, 65-72.
8 DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.   DOI   ScienceOn
9 Diehl JA (2002). Cycling to cancer with cyclin D1. Cancer Biol Ther, 1, 226-31.   DOI
10 Donnellan R, Chetty R (1998). Cyclin D1 and human neoplasia. Mol Pathol, 51, 1-7.   DOI   ScienceOn
11 Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI   ScienceOn
12 Evan GI, Vousden KH (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411, 342-8.   DOI   ScienceOn
13 Fernberg P, Chang ET, Duvefelt K, et al (2010). Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control, 21, 759-69.   DOI
14 Gijtenbeek JM, Boots-Sprenger SH, Franke B, Wesseling P, Jeuken JW (2005). Cyclin D1 genotype and expression in sporadic hemangioblastomas. J Neurooncol, 74, 261-6.   DOI
15 Howe D, Lynas C (2001). The cyclin D1 alternative transcripts (a) and (b) are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica, 86, 563-9.
16 Li Y, Zhang S, Geng JX, et al (2012). Effects of the cyclin D1 polymorphism on lung cancer risk-a meta-analysis. Asian Pac J Cancer Prev, 13, 2325-8.   과학기술학회마을   DOI
17 Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
18 Morton LM, Wang SS, Cozen W, et al (2008). Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood, 112, 5150-60.   DOI
19 Qian PX, Wang L (2012). Correlation between Cyclin D1 gene polymorphism and acute lymphoblastic leukemia in children. Int J Laboratory Med, 33, 1567-8.
20 Morton LM, Purdue MP, Zheng T, et al (2009). Risk of non- Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. Cancer Epidemiol Biomarkers Prev, 18, 1259-70.   DOI   ScienceOn
21 Qiuling S, Yuxin Z, Suhua Z, et al (2003). Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis, 24, 1499-503.   DOI   ScienceOn
22 Rong LC, Xu HY, Rui YY, et al (2010). The association study between the CCND1 G870A polymorphism and risk of children with acute lymphoblastic leukemia. J Nanjing Med Univers, 30, 1700-2
23 Sherr CJ (1995). D-type cyclins. Trends Biochem Sci, 20, 187-90.   DOI   ScienceOn
24 Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47.   DOI   ScienceOn
25 Stieglitz E, Loh ML (2013). Genetic predispositions to childhood leukemia. Ther Adv Hematol, 4, 270-90.   DOI
26 Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 70-1.
27 Tobias A, Campbell MJ (1999). Modelling influenza epidemics in the relation between black smoke and total mortality. A sensitivity analysis. J Epidemiol Community Health, 53, 583-4.   DOI
28 Wang SL, Hou JW, Song J, et al (2006). Approach on the polymorphism of cyclin D1 for chinese children patients with acute lymphoblastic leukemia. Chinese J Clinical Oncol, 33, 126-9.
29 Wang L, Habuchi T, Mitsumori K, et al (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20.   DOI   ScienceOn
30 Wang L, Wang Z, Gao X, et al (2014). Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis. Tumour Biol, 35, 1149-55.   DOI
31 Wang SL, Zhang JB, Huang G, et al (2011). Study of Cyclin D1 gene polymorphism in chronic myelocytic leukemia. Jilin Med J, 32, 7221-4.
32 Wang SS, Cozen W, Severson RK, et al (2006). Cyclin D1 splice variant and risk for non-Hodgkin lymphoma. Hum Genet, 120, 297-300.   DOI
33 Yang Y, Wang F, Shi C, et al (2012). Cyclin D1 G870A polymorphism contributes to colorectal cancer susceptibility: evidence from a systematic review of 22 case-control studies. PLoS One, 7, 36813.   DOI
34 Zeybek U, Yaylim I, Ozkan NE, et al (2013). Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev, 14, 4101-6.   과학기술학회마을   DOI   ScienceOn
35 Hou X, Wang S, Zhou Y, et al (2005). Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. Int J Hematol, 82, 206-9.   DOI